Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).

e15145 Background: docetaxel-based chemotherapy (D-CT) represent the first line standard of care for mCRPC. Because no data exist about the most appropriate treatment duration, a matter of interest in mCRPC, we evaluated the possible advantages of a rechallenge chemotherapy approach. Methods: from July 2000 to March 2010 all consecutive patients treated with docetaxel for mCRPC in our institutions were evaluated for a possible rechallenge D-CT. In non-progressing cases, D-CT was interrupted either because PSA decreased by at least 90% or after a minimum of 6 cycles in the case of a PSA plateau. Median time to definitive progression (TTDP: defined for this protocol as the interval between the first D-CT infusion and the first evidence of definitive biochemical or clinical progression) was the primary end point of the study Results: data relate to the first 62 evaluated patients (median age 73 years; median Gleason score 7; median baseline PSA 53.0 ng/ml), 55 of whom achieved at least a stable disease after...